Merck earnings release, August 4, 2026

Merck & Co., Inc. (MRK) · Form 8-K, Item 2.02 · Filed · SEC filing

- 1 -

Merck & Co., Inc., Rahway, N.J., USA Announces

Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Sales Growth Reflects Continued Strength in

Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR

Financial Highlights

Pipeline & Portfolio Highlights

Full-Year 2026 Financial Outlook¹

Available in some markets as KEYTRUDA SC.

-²

-

RAHWAY, N.J., Aug. 4, 2026 – Merck & Co., Inc., Rahway, N.J.,

USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026.

“We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches,” said Robert M.

Davis, chairman and chief executive officer. “The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease. Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation. I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory.”

Financial Summary

*Refer to table on page 7.

N/M - Not meaningful

For the second quarter of 2026, Generally Accepted

Accounting Principles (GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54 and non-GAAP loss per share was $0.13.

Both the GAAP and non-GAAP loss per share were due to a charge for the acquisition of

Terns

Pharmaceuticals, Inc. (

Terns) of $2.31 per share.

Both GAAP and non-GAAP

EPS in the second quarter of 2025 include a charge of $0.07 per share for an upfront payment related to a license agreement with Jiangsu

Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharma).

Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities. Non-GAAP EPS in the second quarter of 2025 also excludes tax benefits primarily resulting from favorable audit reserve adjustments.

Year-to-date results can be found in the attached tables.²

Net (loss) income attributable to the Company.³

The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.

-³

-

Second-Quarter Sales Performance

The following table reflects sales of the Company’s top products and significant performance drivers.

-⁴

-

*Alliance revenue for this product represents the

Company’s share of profits, which are product sales net of cost of sales and commercialization costs.

**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.

-⁵

-

Second-Quarter Expense and Related Information

The table below presents selected expense information.

GAAP Expense, EPS and Related Information

Gross margin was 73.5% for the second quarter of

2026 compared with 77.5% for the second quarter of 2025.

The decrease was primarily due to higher amortization of intangible assets and inventory write-downs.

Selling, general and administrative (SG&A) expenses were $2.9 billion in the second quarter of 2026, an increase of 10% compared with the second quarter of 2025.

The increase was primarily due to higher administrative costs (including investments in IT), as well as higher promotional costs in support of product launches.

Research and development (R&D) expenses were

$9.7 billion in the second quarter of 2026 compared with $4.0 billion in the second quarter of 2025. The increase was largely due to a

$5.7 billion charge for the acquisition of Terns and higher clinical development spending, partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone Life Sciences (Blackstone). R&D expenses in the second quarter of 2025 include a $200 million charge for an upfront payment related to a license agreement with Hengrui Pharma.

Other (income) expense, net, was $99 million of expense in the second quarter of 2026 compared with $7 million of income in the second quarter of 2025.

The unfavorability was primarily due to higher net interest expense, partially offset by higher net income from investments in equity securities.⁴

Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration,... (truncated) as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair value step-up to inventories for asset acquisitions.

-⁶

-

The income tax provision for the second quarter of 2026 was

$654 million on a pretax loss of $683 million, resulting in an effective income tax rate of (95.9)%.

This effective income tax rate includes a 108.9 percentage point unfavorable impact of the charge for the acquisition of Terns, for which no tax benefit was recorded.

GAAP loss per share was $0.54 for the second quarter of 2026 compared with earnings per share of $1.76 for the second quarter of 2025, largely due to higher charges for business development transactions, reflecting a $2.31 per share charge in the second quarter of 2026 for the acquisition of Terns compared with a $0.07 per share charge in the second quarter of 2025 related to a license agreement with Hengrui Pharma.

Non-GAAP Expense, EPS and Related Information

Non-GAAP gross margin was 81.1% for the second quarter of 2026 compared with 82.2% for the second quarter of 2025.

The decrease was primarily due to higher inventory write-downs.

Non-GAAP SG&A expenses were $2.9 billion in the second quarter of 2026, an increase of 10% compared with the second quarter of 2025.

The increase was primarily due to higher administrative costs (including investments in IT), as well as higher promotional costs in support of product launches.

Non-GAAP R&D expenses were $9.7 billion in the second quarter of 2026 compared with $4.0 billion in the second quarter of 2025. The increase was largely due to a $5.7 billion charge for the acquisition of Terns and higher clinical development spending, partially offset by a $200 million reduction in R&D expenses as part of a funding agreement with Blackstone. R&D expenses in the second quarter of 2025 include a $200 million charge for an upfront payment related to a license agreement with Hengrui Pharma.

Non-GAAP other (income) expense, net, was $290 million of expense in the second quarter of 2026 compared with $54 million of expense in the second quarter of 2025.

The unfavorability was primarily due to higher net interest expense.

The non-GAAP income tax provision for the second quarter of 2026 was

$882 million on pretax income of $550 million, resulting in a non-GAAP effective income tax rate of 160.3%. This effective income tax rate includes a 146.2 percentage point unfavorable impact of the charge for the acquisition of Terns, for which no tax benefit was recorded.

Non-GAAP loss per share was $0.13 for the second quarter of 2026 compared with earnings per share of $2.13 for the second quarter of 2025, largely due to higher charges for business development transactions, reflecting a $2.31 per share charge in the second quarter of 2026 for the acquisition of Terns compared with a $0.07 per share charge in the second quarter of 2025 related to a license agreement with Hengrui Pharma.

-⁷

-

A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the table that follows.

Pipeline and Portfolio Highlights

In the second quarter, the Company achieved key regulatory milestones across the portfolio while continuing to advance its broad and diverse pipeline.⁵

Includes the estimated income tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments for all periods presented. Amount in the second quarter of

2025 also includes a $146 million benefit primarily resulting from favorable audit reserve adjustments.

-⁸

-

-⁹

-

-¹⁰

-

Notable recent news releases on the Company’s pipeline and portfolio are provided in the table that follows. Visit the News Releases section of the Company’s website to read the releases.*

*References in the above news release titles have been modified for the purpose of this announcement.

-¹¹

-

Upcoming Investor Event

The Company will hold an Oncology Investor Event to coincide with the European Society for Medical Oncology Congress 2026 on Monday, Oct. 26, 2026, at 6 p.m. CET / 1 p.m. EDT, during which senior management will provide an update on the Company’s oncology strategy and program. The event will take place in Madrid,

Spain, and will be accessible via live audio webcast at this weblink.

Full-Year 2026 Financial Outlook

The following table summarizes the Company’s full-year financial outlook.

*The Company does not have any non-GAAP adjustments to sales.

**Includes one-time R&D charges of $9.0 billion for the acquisition of Cidara Therapeutics, Inc. (Cidara) and $5.7 billion for the acquisition of Terns. Outlook does not assume any additional significant potential business development transactions.

***Includes one-time charges of $3.62 per share for the acquisition of Cidara and $2.31 per share for the acquisition of Terns.

The Company has not provided a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective income tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot predict with reasonable certainty the amounts necessary for such a reconciliation, including intangible asset impairment charges, legal settlements, and income and losses from investments in equity securities either owned directly or through ownership interests in investment funds, without unreasonable effort. These items are inherently difficult to forecast and could have a significant impact on the Company’s future GAAP results.

The Company is raising and narrowing the range for its full-year sales outlook and now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion, including a positive... (truncated)ange of approximately 1% at mid-July 2026 exchange rates.

The Company now expects the full-year non-GAAP effective income tax rate to be between 35.0% and 36.0%, including the impact of the non-tax deductible one-time charges for the acquisitions of Cidara and Terns.

The Company now expects full-year 2026 non-GAAP

EPS to be between $2.66 and $2.76, including a positive impact from foreign exchange of approximately $0.15 per share at mid-July 2026 exchange rates. This range includes one-time charges of $9.0 billion, or $3.62 per share, related to the acquisition of Cidara and $5.7 billion, or $2.31 per share, related to the acquisition of Terns. This range also includes costs of approximately $0.12 per share to finance the Terns acquisition and advance MK-4208. The charges related to Terns were not previously included in the outlook. In 2025, non-GAAP

EPS of $8.98 was negatively impacted by one-time charges of $0.20 per share in the aggregate related to certain business development transactions.

-¹²

-

Consistent with past practice, the financial outlook does not assume additional significant potential business development transactions.

Earnings Conference Call

Investors, journalists and the general public may access a live audio webcast of the call on Tuesday, Aug. 4, at 9 a.m.

EDT via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available on the Company’s website.

All participants may join the call by dialing (800)

369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

About Our Company

At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J.,

USA

This news release of Merck & Co., Inc., Rahway,

Financial statements

Income Statement

Table 1a (in millions)

2026 – 1Q2026 – 2Q2026 – June YTD2025 – 1Q2025 – 2Q2025 – June YTD2025 – 3Q2025 – 4Q2025 – Full Year% Change – 2Q% Change – Full Year
Sales16,28616,60732,89315,52915,80631,33517,27616,40065,0115.0%5.0%
Costs, Expenses and OtherCost of sales4,1954,3958,5903,4193,5576,9763,8555,55116,38224.0%23.0%
Costs, Expenses and OtherSelling, general and administrative2,7002,9045,6042,5522,6495,2022,6332,89810,73310.0%8.0%
Costs, Expenses and OtherResearch and development12,5929,74122,3333,6214,0487,6694,2343,88615,789
Costs, Expenses and OtherRestructuring costs1951513466956062947213889-73.0%-45.0%
Costs, Expenses and OtherOther (income) expense, net13899237-35-7-43-238432151
Costs, Expenses and Other(Loss) Income Before Taxes-3,534-683-4,2175,9034,99910,9026,7453,42021,067
Costs, Expenses and OtherIncome Tax Provision7096541,3638185711,3889584582,804
Costs, Expenses and OtherNet (Loss) Income-4,243-1,337-5,5805,0854,4289,5145,7872,96218,263
Costs, Expenses and OtherLess: Net (Loss) Income Attributable to Noncontrolling Interests-3-2-56182-19
Costs, Expenses and OtherNet (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA-4,240-1,335-5,5755,0794,4279,5065,7852,96318,254
Costs, Expenses and Other(Loss) Earnings per Common Share Assuming Dilution (1)-1.72-0.54-2.262.011.763.772.321.197.28
Costs, Expenses and OtherAverage Shares Outstanding Assuming Dilution (1)2,4722,4702,4712,5312,5132,5222,4982,4882,507
Costs, Expenses and OtherTax Rate-20.1%-95.9%-32.313.9%11.4%12.7%14.2%13.4%13.3

Income Statement

Table 2b (in millions)

GAAPAcquisition- and Divestiture-Related Costs (1)Restructuring Costs (2)(Income) Loss from Investments in Equity SecuritiesCertain Other ItemsAdjustment SubtotalNon-GAAP
Second QuarterCost of sales3,5575761657412,816
Second QuarterSelling, general and administrative2,649151162,633
Second QuarterResearch and development4,048353563,992
Second QuarterRestructuring costs560560560
Second QuarterOther (income) expense, net-7-61-6154
Second QuarterIncome Before Taxes4,999-594-77961-1,3126,311
Second QuarterIncome Tax Provision (Benefit)571-3-3-3-146-373944
Second QuarterNet Income4,428-492-64047146-9395,367
Second QuarterNet Income Attributable to Merck & Co., Inc., Rahway, N.J., USA4,427-492-64047146-9395,366
Second QuarterEarnings per Common Share Assuming Dilution1.76-0.2-0.250.020.06-0.372.13
Second QuarterTax Rate11.4%15
June YTDCost of sales6,9761,1962011,3975,579
June YTDSelling, general and administrative5,202381395,163
June YTDResearch and development7,6691053637,606
June YTDRestructuring costs629629629
June YTDOther (income) expense, net-43-3-168-171128
June YTDIncome Before Taxes10,902-1,241-884168-1,95712,859
June YTDIncome Tax Provision (Benefit)1,388-3-3-3-146-4861,874
June YTDNet Income9,514-1,022-727132146-1,47110,985
June YTDNet Income Attributable to Merck & Co., Inc., Rahway, N.J., USA9,506-1,022-727132146-1,47110,977
June YTDEarnings per Common Share Assuming Dilution3.77-0.4-0.290.050.06-0.584.35
June YTDTax Rate12.7%14.6

Income Statement

Acquisition- and Divestiture- Related Costs4 — The table below presents selected expense information. (in millions)

Second Quarter 2026 – GAAPSecond Quarter 2026 – Acquisition- and Divestiture- Related Costs4Second Quarter 2026 – Restructuring CostsSecond Quarter 2026 – (Income) Loss From Investments in Equity SecuritiesSecond Quarter 2026 – Non- GAAP3
Cost of sales4,3951,0671843,144
Selling, general and administrative2,904172,887
Research and development9,7416-19,736
Restructuring costs151151
Other (income) expense, net99-191290
Second Quarter 2025Cost of sales3,5575761652,816
Second Quarter 2025Selling, general and administrative2,6491512,633
Second Quarter 2025Research and development4,0483533,992
Second Quarter 2025Restructuring costs560560
Second Quarter 2025Other (income) expense, net-7-6154

Income Statement

Second Quarter — A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the table that follows. (in millions)

Second Quarter – 2026Second Quarter – 2025
EPSGAAP EPS-0.541.76
EPSDifference0.410.37
EPSNon-GAAP EPS that excludes items listed below3-0.132.13
Net (Loss) IncomeGAAP net (loss) income2-1,3354,427
Net (Loss) IncomeDifference1,005939
Net (Loss) IncomeNon-GAAP net (loss) income that excludes items listed below2,3-3305,366
Excluded Items:Acquisition- and divestiture-related costs41,090594
Excluded Items:Restructuring costs334779
Excluded Items:Income from investments in equity securities-191-61

Income Statement

Table 1 (in millions)

GAAP – 2Q26GAAP – 2Q25% ChangeGAAP – June YTD 2026GAAP – June YTD 2025% Change
Sales16,60715,8065.0%32,89331,3355.0%
Costs, Expenses and OtherCost of sales4,3953,55724.0%8,5906,97623.0%
Costs, Expenses and OtherSelling, general and administrative2,9042,64910.0%5,6045,2028.0%
Costs, Expenses and OtherResearch and development9,7414,04822,3337,669
Costs, Expenses and OtherRestructuring costs151560-73.0%346629-45.0%
Costs, Expenses and OtherOther (income) expense, net99-7237-43
Costs, Expenses and Other(Loss) Income Before Taxes-6834,999-4,21710,902
Costs, Expenses and OtherIncome Tax Provision6545711,3631,388
Costs, Expenses and OtherNet (Loss) Income-1,3374,428-5,5809,514
Costs, Expenses and OtherLess: Net (Loss) Income Attributable to Noncontrolling Interests-21-58
Costs, Expenses and OtherNet (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA-1,3354,427-5,5759,506
Costs, Expenses and Other(Loss) Earnings per Common Share Assuming Dilution (1)-0.541.76-2.263.77
Costs, Expenses and OtherAverage Shares Outstanding Assuming Dilution (1)2,4702,5132,4712,522
Costs, Expenses and OtherTax Rate-95.9%11.4%-32.3%12.7%

Income Statement

Acquisition- and Divestiture-Related Costs (1) — Table 2a

Second Quarter – GAAPSecond Quarter – Acquisition- and Divestiture-Related Costs (1)Second QuarterSecond Quarter – Restructuring Costs (2)Second QuarterSecond Quarter – (Income) Loss from Investments in Equity SecuritiesSecond QuarterSecond Quarter – Adjustment SubtotalSecond Quarter – Non-GAAP
Cost of sales4,3951,0671841,2513,144
Selling, general and administrative2,90417172,887
Research and development9,7416-1)59,736
Restructuring costs151151151
Other (income) expense, net99-191)-191290
Loss Before Taxes-683-1,090)-334)191-1,233550
Income Tax Provision (Benefit)654-219-3-50-341-3-228882
Net Loss-1,337-871)-284)150-1,005-332
Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA-1,335-871)-284)150-1,005-330
Loss per Common Share Assuming Dilution (4)-0.54-0.35)-0.12)0.06-0.41-0.13
Tax Rate-95.9160.3
June YTDCost of sales8,5902,0814212,5026,088
June YTDSelling, general and administrative5,60449495,555
June YTDResearch and development22,3336333922,294
June YTDRestructuring costs346346346
June YTDOther (income) expense, net237-371)-371608
June YTDLoss Before Taxes-4,217-2,136)-800)371-2,565-1,652
June YTDIncome Tax Provision (Benefit)1,363-421-3-135-380-3-4761,839
June YTDNet Loss-5,580-1,715)-665)291-2,089-3,491
June YTDNet Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA-5,575-1,715)-665)291-2,089-3,486
June YTDLoss per Common Share Assuming Dilution (4)-2.26-0.7)-0.27)0.12-0.85-1.41
June YTDTax Rate-32.3-111.3
Full release

N.J., USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful.

If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

-¹³

-

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual

Report on Form 10-K for the year ended December 31, 2025 and the Company’s other filings with the Securities and Exchange Commission

(SEC) available at the SEC’s Internet site ( www.sec.gov).

Appendix

Generic product names are provided below.

Pharmaceutical

BRIDION

(sugammadex)

CAPVAXIVE

(Pneumococcal 21-valent Conjugate Vaccine)

ENFLONSIA

(clesrovimab-cfor)

GARDASIL

(

Human Papillomavirus Quadrivalent [Types 6,

11, 16 and 18] Vaccine, Recombinant)

GARDASIL 9

(Human Papillomavirus 9-valent Vaccine, Recombinant)

JANUMET

(sitagliptin and metformin HCl)

JANUVIA

(sitagliptin)

KEYTRUDA

(pembrolizumab)

KEYTRUDA QLEX

(pembrolizumab and berahyaluronidase alfa-pmph)

LAGEVRIO

(molnupiravir)

Lenvima

(lenvatinib)

LIPFENDRA

(enlicitide)

Lynparza

(olaparib)

M-M-R II

(Measles, Mumps and Rubella Virus Vaccine Live)

OHTUVAYRE

(ensifentrine)

PREVYMIS

( letermovir)

PROQUAD

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

VARIVAX

(Varicella Virus Vaccine Live)

VAXNEUVANCE

(Pneumococcal 15-valent Conjugate Vaccine)

WELIREG

( belzutifan)

WINREVAIR

(sotatercept-csrk)

-¹⁴

-

Animal Health

BRAVECTO

(fluralaner)

###

MERCK & CO., INC., RAHWAY, N.J., USA

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Merck earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.